Max Fehlmann
Gründer bei Consortium Québécois sur la Découverte du Médicament
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Rosemonde Mandeville | M | - |
Cancer Research Society
Cancer Research Society Miscellaneous Commercial ServicesCommercial Services The Cancer Research Society is a non-profit organization that focuses on cancer research. The organization is based in Montreal, Canada. The organization has received support from Stéphane Rousseau, who is a spokesperson for the organization and actively supports their efforts. Max Fehlmann has been the CEO of the Canadian company since 2017. | - |
Louise Proulx | M | 73 |
Consortium Québécois sur la Découverte du Médicament
Consortium Québécois sur la Découverte du Médicament Miscellaneous Commercial ServicesCommercial Services Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann. | - |
Ali Tehrani | M | 52 |
Consortium Québécois sur la Découverte du Médicament
Consortium Québécois sur la Découverte du Médicament Miscellaneous Commercial ServicesCommercial Services Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann. | - |
Frederic Ors | M | 50 |
Consortium Québécois sur la Découverte du Médicament
Consortium Québécois sur la Découverte du Médicament Miscellaneous Commercial ServicesCommercial Services Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
M. Desbiens | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | 5 Jahre |
Siegfried Hekimi | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | 12 Jahre |
Yves Fouron | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | - |
Pascal Puchois | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | 5 Jahre |
Nahed K. Ahmed | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | - |
Jean-Marie Houle | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | 4 Jahre |
Monique Mercier | F | 67 |
Cancer Research Society
Cancer Research Society Miscellaneous Commercial ServicesCommercial Services The Cancer Research Society is a non-profit organization that focuses on cancer research. The organization is based in Montreal, Canada. The organization has received support from Stéphane Rousseau, who is a spokesperson for the organization and actively supports their efforts. Max Fehlmann has been the CEO of the Canadian company since 2017. | 7 Jahre |
Endri Leno | M | - |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | - |
Luc Paquet | M | 59 |
Consortium Québécois sur la Découverte du Médicament
Consortium Québécois sur la Découverte du Médicament Miscellaneous Commercial ServicesCommercial Services Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Kanada | 13 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Max Fehlmann
- Persönliches Netzwerk